Shandong Cancer Hospital and Institute, Jinan, China
Yanxin Sun , Yuping Sun , Juan Li , Aiqin Gao
Background: Growing researches have focused on obesity as an useful prognostic factor for pan-cancer patients with immmnotherapy. The role of body-mass index (BMI) in predicting response to ICIs is not consistent in different tumors. This meta-analysis was conducted to evaluate the relationship between BMI and outcome in patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors, which is not clear as studies have demonstrated inconsistent results and significant interpretation biases. Methods: We searched PubMed and Embase, for relevant studies published up to December 2022. Title/abstract screening, full-text review, data extraction, and quality assessment were performed independently. Results: The correlation between BMI and prognosis in patients with advanced non-small cell lung cancer treated with ICIs was compared in ten trials encompassing 5000 individuals with the disease. The findings showedthat immunotherapy was significantly more effective for non-small cell lung cancer patients with a higher BMI compared to those with a lower BMI (OS: HR: 0.832, 95% CI: 0.725-0.955, p = 0.009; PFS: HR: 0.860, 95% CI: 0.771-0.960, p = 0.007). While,in the investigation of the obese group, no statistically significant differences were found. Conclusions: In patients with advanced non-small cell lung cancer treated with ICIs, appropriate higher BMI was significantly linked to better outcomes. However, discrepant findings from different cutoff subgroup analyses urgently call for further analysis.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2024 ASCO Gastrointestinal Cancers Symposium
First Author: Mario Machado Lopes
2022 ASCO Annual Meeting
First Author: Hassan Mohammed Abushukair
2022 ASCO Annual Meeting
First Author: Giuseppe Viscardi
2024 ASCO Genitourinary Cancers Symposium
First Author: Yu Fujiwara